Editorial for "Potential Anti-Human Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer"

被引：0
|
作者：
Geitung, Jonn Terje [1 ,2 ]
机构：
[1] Univ Oslo, Oslo, Norway
[2] Akershus Univ Hosp, Oslo, Norway
来源：
JOURNAL OF MAGNETIC RESONANCE IMAGING | 2023年 / 58卷 / 05期
关键词：
D O I：
10.1002/jmri.28626
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：1615 / 1616
页数：2
相关论文
共 50 条
  • [41] Targeting human epidermal growth factor receptor 2: It is time to kill kinase death human epidermal growth factor receptor 3
    Menendez, Javier A.
    Lupu, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) : 2496 - 2498
  • [42] Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Wolff, Antonio C.
    Tung, Nadine M.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2189 - +
  • [43] Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation
    Yang, Ellen
    D'Alfonso, Timothy M.
    Morrow, Monica
    Brogi, Edi
    Wen, Hannah Y.
    HISTOPATHOLOGY, 2025, 86 (03) : 441 - 449
  • [44] The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer
    Li, Guo-Cai
    Jia, Xu-Chun
    Zhao, Qing-Chuan
    Zhang, Hong-Wei
    Yang, Peng
    Xu, Long-Long
    Pang, Fang-Ning
    Sun, Jian-Bing
    MEDICINE, 2020, 99 (21) : E20460
  • [45] Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer
    Johnston, SRD
    CLINICAL CANCER RESEARCH, 2006, 12 (03) : 1061S - 1068S
  • [46] Utilization of Hypofractionated Whole-Breast Radiotherapy with Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy
    Sayan, M.
    Vergalasova, I.
    Jhawar, S. R.
    Toppmeyer, D.
    Haffty, B. G., Jr.
    Ohri, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E31 - E32
  • [47] The Significance of Recognition of Human Epidermal Growth Factor 2 Low in Breast Cancer Therapy
    Tozbikian, Gary
    ADVANCES IN ANATOMIC PATHOLOGY, 2023, 30 (06) : 388 - 396
  • [48] Utilization of Hypofractionated Whole-Breast Radiotherapy With Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy
    Sayan, Mutlay
    Vergalasova, Irina
    Jhawar, Sachin
    Kumar, Shicha
    George, Mridula
    Kowzun, Maria
    Potdevin, Lindsay
    Toppmeyer, Deborah
    Haffty, Bruce
    Ohri, Nisha
    CLINICAL BREAST CANCER, 2021, 21 (01) : 31 - 36
  • [49] Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
    Ogitani, Yusuke
    Hagihara, Katsunobu
    Oitate, Masataka
    Naito, Hiroyuki
    Agatsuma, Toshinori
    CANCER SCIENCE, 2016, 107 (07) : 1039 - 1046
  • [50] Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study
    Musolino, Antonino
    Michiara, Maria
    Conti, Giovanni Maria
    Boggiani, Daniela
    Zatelli, Marella
    Palleschi, Dario
    Bella, Maria Angela
    Sgargi, Paolo
    Di Blasio, Beatrice
    Ardizzoni, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) : 2362 - 2368
12345